NAUT - Nautilus Biotechnology - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

NAUT is currently covered by 2 analysts with an average price target of $2.06. This is a potential upside of $1.35 (190.14%) from yesterday's end of day stock price of $0.71.

Nautilus Biotechnology's activity chart (see below) currently has 9 price targets and 9 ratings on display. The stock rating distribution of NAUT is 66.67% HOLD and 33.33% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 33.33% with an average time for these price targets to be met of 55.5 days.

Highest price target for NAUT is $1.75, Lowest price target is $1.75, average price target is $1.75.

Most recent stock forecast was given by MATTHEW SYKES from GOLDMAN SACHS on 05-Dec-2024. First documented stock forecast 04-Aug-2021.

Best performing analysts who are covering NAUT - Nautilus Biotechnology:

Matthew Sykes Tejas Savant

Currently out of the existing stock ratings of NAUT, 2 are a HOLD (66.67%), 1 are a SELL (33.33%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sell

$1.75

$0.64 (57.66%)

$3

8 months 11 days ago
(05-Dec-2024)

4/6 (66.67%)

$-0.17 (-8.85%)

111

Hold

$6

$4.89 (440.54%)

$6

2 years 13 days ago
(03-Aug-2023)

0/2 (0%)

$2.86 (91.08%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is NAUT (Nautilus Biotechnology) average time for price targets to be met?

On average it took 55.5 days on average for the stock forecasts to be realized with a an average price target met ratio 33.33

Which analyst has the current highest performing score on NAUT (Nautilus Biotechnology) with a proven track record?

MATTHEW SYKES

Which analyst has the current lower performing score on NAUT (Nautilus Biotechnology) with a proven track record?

TEJAS SAVANT

Which analyst has the most public recommendations on NAUT (Nautilus Biotechnology)?

Matthew Sykes works at GOLDMAN SACHS and has 4 price targets and 5 ratings on NAUT

Which analyst is the currently most bullish on NAUT (Nautilus Biotechnology)?

Tejas Savant with highest potential upside - $4.89

Which analyst is the currently most reserved on NAUT (Nautilus Biotechnology)?

Matthew Sykes with lowest potential downside - $0.64

Nautilus Biotechnology in the News

Nautilus Biotechnology Reports Second Quarter 2025 Financial Results

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. “In Q2, we achieved major milestones that underscore the continued advancement of our platform,” said Sujal Patel, CEO of Nautilus Biotechnology. “Not...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?